Ambrx Biopharma Inc. is a clinical-stage biologics company focused on discovering and developing a novel class of engineered precision biologics (EPBs) using their proprietary expanded genetic code technology platform that allows them to incorporate, in a site-specific manner, synthetic amino acids (SAAs) into proteins within living cells. Their product candidates are designed to overcome the inherent limitations of conventional conjugation approaches that use natural amino acids for non-site-specific conjugation, offering potential safety and efficacy benefits to treat patients across multiple therapeutic areas. The Company’s most advanced internal product candidate is ARX788, an anti-HER2 ADC, currently being investigated in multiple clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction (GEJ) cancer and other solid tumors, including an ongoing Phase 2/3 clinical trial for the treatment of HER2-positive metastatic breast cancer.